|
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation |
Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technology Assessment 2011; 15(14): 1-278 Indexing Status Subject indexing assigned by NLM MeSH Abatacept; Adalimumab; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived /economics /therapeutic use; Antirheumatic Agents /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy /economics /pathology; Etanercept; Great Britain; Humans; Immunoconjugates /economics /therapeutic use; Immunoglobulin G /economics /therapeutic use; Infliximab; Receptors, Tumor Necrosis Factor /therapeutic use; Rituximab; Tumor Necrosis Factor-alpha /antagonists & inhibitors AccessionNumber 12011003261 Date bibliographic record published 15/06/2011 |
|
|
|